| 期 |
栏目 |
标题 |
文件 |
| 卷 11, 编号 1 (2009) |
Articles |
Bevatsizumab (Avastin) v kombinatsii s taksanami v 1-y linii lecheniya HER-2-negativnogo metastaticheskogo raka molochnoy zhelezy(Rezul'taty issledovaniya AVADO) |
|
| 卷 11, 编号 1 (2009) |
Articles |
Dlitel'noe i bezopasnoe primenenie Avastina pri metastaticheskom kolorektal'nom rake: klinicheskiy opyt primeneniya |
|
| 卷 11, 编号 3 (2009) |
Articles |
Klinicheskaya effektivnost'i bezopasnost' primeneniya otechestvennogo rekombinantnogo granulotsitarnogo koloniestimuliruyushchego faktora Neypomaks® u bol'nykh rakom molochnoy zhelezy, poluchayushchikh khimioterapiyu doksorubitsinom i dotsetakselom |
|
| 卷 12, 编号 1 (2010) |
Articles |
Sovremennye aspektyprofilaktiki neytropeniipri khimioterapii solidnykh opukholey |
|
| 卷 12, 编号 3 (2010) |
Articles |
Bevatsizumab v lechenii HER2-negativnogometastaticheskogo raka molochnoy zhelezy:sovremennye dannye ob effektivnostii bezopasnosti |
|
| 卷 13, 编号 2 (2011) |
Articles |
Klinicheskie rekomendatsii po profilaktikei lecheniyu toshnoty i rvoty u bol'nykh,poluchayushchikh khimio- i luchevuyuprotivoopukholevuyu terapiyu |
|
| 卷 17, 编号 1 (2015) |
Articles |
The improvement in overall survival for patients with metastatic breast cancer treated with eribulin: the resolution based on results of the expert council |
|
| 卷 18, 编号 2 (2016) |
Articles |
Development of cytotoxic chemotherapy in metastatic breast cancer with a triple-negative phenotype |
(Rus)
|
| 卷 13, 编号 1 (2011) |
Articles |
Opyt dlitel'nogo primeneniya kombinatsii kapetsitabina, lapatiniba i trastuzumabapri HER-2-pozitivnom metastaticheskom rake molochnoy zhelezy. Opisanie klinicheskogo sluchaya |
|
| 卷 13, 编号 4 (2011) |
Articles |
Antiangiogennaya terapiyapri rake molochnoy zhelezys troynym negativnym fenotipom |
|
